Dyne Therapeutics, Inc. (DYN) |
24.87 1.01 (4.23%) 04-22 16:00 |
Open: | 24.28 |
High: | 25.185 |
Low: | 23.59 |
Volume: | 713,311 |
Market Cap: | 2,017(M) |
PE Ratio: | -6.3 |
Exchange: | NASDAQ Global Select |
Industry: | Biotechnology |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 29.80 |
Resistance 1: | 27.24 |
Pivot price: | 26.06 |
Support 1: | 23.11 |
Support 2: | 19.23 |
52w High: | 30.269 |
52w Low: | 6.4 |
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
EPS | -3.950 |
Book Value | 1.490 |
PEG Ratio | 0.00 |
Gross Profit | 0.000 |
Profit Margin (%) | 0.00 |
Operating Margin (%) | 0.00 |
Return on Assets (ttm) | -64.2 |
Return on Equity (ttm) | -137.3 |
Mon, 25 Mar 2024
Dyne Therapeutics Announces CEO Transition - GlobeNewswire
Fri, 15 Mar 2024
Chief Operating Officer Of Dyne Therapeutics Sold 71% Of Their Shares - Simply Wall St
Tue, 05 Mar 2024
Dyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - Yahoo Finance
Wed, 21 Feb 2024
Dyne Therapeutics: An Updated Analysis (NASDAQ:DYN) - Seeking Alpha
Fri, 26 Jan 2024
Dyne Therapeutics stock jumps amid report of takeover interest - Seeking Alpha
Fri, 26 Jan 2024
Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN) - Yahoo Finance
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |